FrancophonIA/ELRC3.0 huggingface dataset:
English: Cerebral oedema, Acute aseptic meningitis with meningism (paralysis, vomiting), Lethargy,
Slovenian: akutni aseptični meningitis z meningizmom (paralizo, bruhanjem), letargija, prehodna blaga kognitivna motnja, psihoze, afazija,
English: Infections
Slovenian: ZDRAVILA
English: − loss of sex drive, erection problems, vaginal discharge, infertility, enlargement of the breasts in men (gynaecomastia) − fever.
Slovenian: − izguba libida, težave z erekcijo, nožnični izcedek, neplodnost, povečanje prsi pri moških
English: Recommended dose
Slovenian: − Navodilo shranite.
English: − lymphoma (lump in neck, groin or armpits with associated backache, weight loss or night sweats)
Slovenian: − limfom (oteklina na vratu, v dimljah ali pod pazduhama, ki ji je pridružena bolečina v hrbtu,
English: Your doctor must carry out investigations and laboratory tests in order to detect these effects as early as possible.
Slovenian: Za njihovo pravočasno prepoznavanje bo vaš zdravnik opravil preiskave in laboratorijske teste.
English: The prescriber should make sure patients understand that Jylamvo (methotrexate) should only be taken once a week.
Slovenian: Zdravnik, ki predpisuje zdravilo, se mora prepričati, da bolniki razumejo, da smejo zdravilo Jylamvo
English: Dosage in adult rheumatoid arthritis: The usual initial dose is 7.5 mg (3.75 ml), once a week.
Slovenian: Običajni začetni odmerek je 7,5 mg (3,75 ml) enkrat tedensko.
English: Symptoms of overdose are e.g. sore throat, fever, mouth ulcers, diarrhoea, vomiting, skin rashes, bleeding or unusual weakness.
Slovenian: Simptomi prevelikega odmerjanja so npr. vnetje žrela, zvišana telesna temperatura, razjede v ustih, driska,
English: Diabetes mellitus
Slovenian: Kreatininski očistek
English: See also section “Pregnancy, breast-feeding and fertility”.
Slovenian: Glejte tudi poglavje „Nosečnost,
English: Oral solution 60 ml bottle Bottle adaptor 10 ml dosing syringe
Slovenian: Steklenička 60 ml Nastavek za stekleničko
English: especially bone marrow depression.
Slovenian: zlasti z zaviranjem delovanja kostnega mozga.
English: Loss of appetite, Nausea, Vomiting, Abdominal pain,
Slovenian: Bolezni prebavil izguba teka, navzeja, bruhanje,
English: Excipient warnings
Slovenian: peroralna raztopina
English: Methotrexate-induced haematopoietic suppression may occur abruptly and with apparently safe dosages.
Slovenian: Nenadoma in pri na videz varnih odmerkih metotreksata lahko pride do z metotreksatom povzročene zavore hematopoeze.
English: Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Slovenian: neznana pogostnost (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov) V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
English: Pulmonary fibrosis
Slovenian: Žilne bolezni tromboembolične reakcije
English: • Information on treatment with Jylamvo, administration and posology.
Slovenian: • informacije glede zdravljenja z zdravilom Jylamvo, uporabe in odmerjanja
English: − blood test showing raised liver enzymes.
Slovenian: vnetje in razjede v ustih in žrelu, − izvidi preiskav krvi, ki kažejo zvišane vrednosti jetrnih encimov.
English: − diabetes
Slovenian: − sladkorna bolezen,
English: − inflammation of the pancreas, inflammation of the digestive tract, bloody stools, inflamed gums,
Slovenian: − vnetje trebušne slinavke, vnetje prebavil, krvavo blato, vnetje dlesni, prebavne motnje,
English: − loss of appetite, feeling sick (nausea), vomiting, abdominal pain, indigestion, inflammation and ulcers of the mouth and throat
Slovenian: − izguba teka, slabost (siljenje na bruhanje), bruhanje, bolečine v trebuhu, prebavne motnje,
English: Methotrexate has moderate influence on the ability to drive and use machines, since central nervous system disorders such as tiredness, dizzy spells or drowsiness can occur during treatment.
Slovenian: Med zdravljenjem z zdravilom Jylamvo se lahko pojavijo neželeni učinki, ki vplivajo na osrednje živčevje, npr. utrujenost in omotica.
English: You must talk to a doctor if you do not feel better or if you feel worse
Slovenian: Če se znaki vaše bolezni poslabšajo ali ne izboljšajo, se posvetujte z zdravnikom.
English: Male Fertility
Slovenian: Plodnost pri moških
English: It is particularly important to tell your doctor if you are using the following medicines: - other medicines for rheumatoid arthritis or psoriasis, such as leflunomide, azathioprine (also used to prevent rejection after an organ transplant), sulfasalazine (also used for ulcerative colitis) - ciclosporin (for supressing the immune system) - non-steroidal anti-inflammatory drugs or salicylates (medicines against pain and/or inflammation such as acetylsalicylic acid, diclofenac and ibuprofen or pyrazole) - live vaccines
Slovenian: − nesteroidna protivnetna zdravila ali salicilate (protibolečinska in/ali protivnetna zdravila, kot so acetilsalicilna kislina, diklofenak in ibuprofen ali pirazol), − živa cepiva,
English: • Stomatitis, ulcers of the oral cavity and known active gastrointestinal ulcers
Slovenian: • stomatitis, razjede v ustni votlini in znane aktivne ulkusne bolezni prebavil; • dojenje (glejte poglavje 4.6);
English: Elderly
Slovenian: Bata
English: Elimination in patients with impaired renal function is markedly delayed.
Slovenian: Pri okvari ledvic se izločanje znatno podaljša.
English: Before the beginning of treatment
Slovenian: DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
English: Osteonecrosis of jaw (secondary to lymphoprolifer -ative disorders)
Slovenian: Bolezni mišično skeletnega sistema in vezivnega tkiva osteoporoza artralgija mialgija stresni zlom osteonekroza čeljusti (kot posledica limfoprolifer -ativnih bolezni)
English: − severe visual disorders
Slovenian: − učinkuje protivnetno.
English: Enlarged lymph nodes (lymphoma) may occur in patients receiving low dose methotrexate and if this is the case, therapy must be stopped.
Slovenian: Pri bolnikih, ki prejemajo majhne odmerke metotreksata, se lahko pojavijo otekle bezgavke (limfom);
English: Vitamin preparations or other products containing folic acid, folinic acid or their derivatives may decrease the effectiveness of methotrexate (see sections 4.2 and 4.5).
Slovenian: Vitaminski pripravki ali drugi izdelki, ki vsebujejo folno kislino, folinsko kislino ali njune derivate,
English: − pain or difficulties in passing urine
Slovenian: Splošne težave in spremembe na mestu aplikacije zvišana telesna temperatura
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pioglitazone Accord on 21 March 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Pioglitazone Accord, veljavno po vsej Evropski uniji, izdala 21. marca 2012.
English: Treatment with Pioglitazone Accord should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Slovenian: Zdravljenje z zdravilom Pioglitazone Accord je treba ponovno oceniti po treh do šest mesecih in ga pri bolnikih, ki od njega nimajo zadostne koristi, prekiniti.
English: The full EPAR for Pioglitazone Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pioglitazone Accord je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Pioglitazone Accord pioglitazone
Slovenian: Pioglitazone Accord pioglitazon
English: As a consequence, the blood glucose levels are reduced and this helps to control type 2 diabetes.
Slovenian: Posledično se raven glukoze v krvi zniža, kar pripomore k boljšemu uravnavanju sladkorne bolezni tipa 2.
English: Pioglitazone Accord is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Slovenian: Zdravilo Pioglitazone Accord se uporablja za zdravljenje sladkorne bolezni tipa 2 pri odraslih (starejših od 18 let), zlasti tistih s prekomerno telesno maso.
English: This is a summary of the European public assessment report (EPAR) for Pioglitazone Accord.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pioglitazone Accord.
English: What measures are being taken to ensure the safe and effective use of Pioglitazone Accord?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pioglitazone Accord?
English: The company that markets Pioglitazone Accord will produce educational material for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.
Slovenian: Družba, ki trži zdravilo Pioglitazone Accord, bo za zdravnike, ki bodo predpisovali zdravilo, pripravila izobraževalno gradivo, ki bo vključevalo možno tveganje za srčno popuščanje in rak sečnega mehurja pri zdravljenju s pioglitazonom, merila za izbiro bolnikov in potrebo po redni oceni zdravljenja ter njegovi prekinitvi, če to bolnikom ne koristi več.
English: This means that Pioglitazone Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
English: The active substance in Pioglitazone Accord, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Slovenian: Zdravilna učinkovina v zdravilu Pioglitazone Accord, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pioglitazone Accord has been shown to have comparable quality and to be bioequivalent to Actos.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pioglitazone Accord primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
English: The Committee recommended that Pioglitazone Accord be approved for use in the EU.
Slovenian: Priporočil je, da se zdravilo Pioglitazone Accord odobri za uporabo v EU.
English: The medicine is available as tablets (15, 30 and 45 mg) and the recommended starting dose is 15 or 30 mg once a day.
Slovenian: Zdravilo je na voljo v obliki tablet (15, 30 in 45 mg), priporočeni začetni odmerek pa je 15 ali 30 mg enkrat na dan. Odmerek bo po enem ali dveh tednih morda treba povečati do 45 mg enkrat na dan, če je treba izboljšati uravnavanje glukoze (sladkorja) v krvi.
English: Because Pioglitazone Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Pioglitazone Accord generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: For more information about treatment with Pioglitazone Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Pioglitazone Accord preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What is Pioglitazone Accord and what is it used for?
Slovenian: Kaj je zdravilo Pioglitazone Accord in za kaj se uporablja?
English: What are the benefits and risks of Pioglitazone Accord?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Pioglitazone Accord?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pioglitazone Accord have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Pioglitazone Accord upoštevati zdravstveni delavci in bolniki, so prav tako vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Pioglitazone Accord is a ‘generic medicine'.
Slovenian: Zdravilo Pioglitazone Accord je „generično zdravilo“.
English: Other information about Pioglitazone Accord
Slovenian: Druge informacije o zdravilu Pioglitazone Accord
English: Because Pioglitazone Accord is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Slovenian: Ker je zdravilo Pioglitazone Accord generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
English: • in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone;
Slovenian: • v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče zadovoljivo uravnati bolezni, ali v kombinaciji s sulfonilsečnino (drugo vrsto zdravila za zdravljenje sladkorne bolezni), če metformin ni primeren pri tistih bolnikih, pri katerih sladkorna bolezen zgolj s sulfonilsečnino ni zadovoljivo uravnana;
English: • together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Slovenian: • skupaj z insulinom pri bolnikih, pri katerih bolezen ni zadovoljivo uravnavana zgolj z insulinom in za katere metformin ni primeren.
English: Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk.
Slovenian: Zato je menil, da njegove koristi enako kot pri zdravilu Actos odtehtajo znana tveganja.
English: For practical information about using Pioglitazone Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Pioglitazone Accord naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: • on its own in patients for whom metformin (another diabetes medicine) is not suitable.
Slovenian: • kot samostojno zdravilo pri bolnikih, za katere metformin (drugo zdravilo za zdravljenje sladkorne bolezni) ni primeren;
English: It is not intended to provide practical advice on how to use Pioglitazone Accord.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: • together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite treatment with two medicines by mouth;
Slovenian: • skupaj z metforminom in sulfonilsečnino pri bolnikih, pri katerih kljub peroralnemu zdravljenju s tema dvema zdraviloma bolezen ni zadovoljivo uravnana;
English: At subsequent reviews prescribers should confirm that benefits to patients are maintained.
Slovenian: Pri nadaljnjih pregledih morajo zdravniki, ki zdravilo predpisujejo, preveriti, ali še vedno zagotavlja enake koristi.
English: Pioglitazone Accord contains the active substance pioglitazone.
Slovenian: Zdravilo Pioglitazone Accord vsebuje zdravilno učinkovino pioglitazon.
English: Why is Pioglitazone Accord approved?
Slovenian: Zakaj je bilo zdravilo Pioglitazone Accord odobreno?
English: Pioglitazone Accord can only be obtained with a prescription.
Slovenian: Predpisovanje in izdaja zdravila Pioglitazone Accord je le na recept.
English: How has Pioglitazone Accord been studied?
Slovenian: Kako je bilo zdravilo Pioglitazone Accord raziskano?
English: How does Pioglitazone Accord work?
Slovenian: Kako zdravilo Pioglitazone Accord deluje?
English: How is Pioglitazone Accord used?
Slovenian: Kako se zdravilo Pioglitazone Accord uporablja?
English: Women should also not become pregnant for one month after stopping treatment.
Slovenian: Ženske prav tako ne smejo zanositi še en mesec po koncu zdravljenja.
English: What measures are being taken to ensure the safe and effective use of Opsumit?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Opsumit?
English: The medicine is available as 10 mg tablets and taken at a dose of one tablet every day.
Slovenian: Zdravilo je na voljo v obliki 10-miligramskih tablet in se jemlje v odmerku ena tableta vsak dan.
English: Opsumit received a marketing authorisation valid throughout the EU on 20 December 2013.
Slovenian: Za zdravilo Opsumit je bilo 20. decembra 2013 izdano dovoljenje za promet, veljavno po vsej EU.
English: The European Medicines Agency decided that Opsumit's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Opsumit večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: What is Opsumit and what is it used for?
Slovenian: Kaj je zdravilo Opsumit in za kaj se uporablja?
English: Other information about Opsumit
Slovenian: Druge informacije o zdravilu Opsumit
English: As for all medicines, data on the use of Opsumit are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Opsumit stalno spremljajo.
English: Further information on Opsumit can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije o zdravilu Opsumit so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What benefits of Opsumit have been shown in studies?
Slovenian: Kakšne koristi zdravila Opsumit so se pokazale v študijah?
English: Why is Opsumit authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Opsumit odobreno v EU?
English: What are the risks associated with Opsumit?
Slovenian: Kakšna tveganja so povezana z zdravilom Opsumit?
English: These are part of a natural mechanism in the body that can cause arteries to narrow.
Slovenian: Ti so del naravnega telesnega mehanizma, ki lahko povzroči zožitev arterij.
English: An overview of Opsumit and why it is authorised in the EU
Slovenian: Pregled zdravila Opsumit in zakaj je odobreno v EU
English: In a main study involving 742 patients, Opsumit has been shown to reduce the risk of PAH-related illness, particularly the worsening of PAH symptoms.
Slovenian: V glavni študiji, v katero je bilo vključenih 742 bolnikov, so pokazali, da zdravilo Opsumit zmanjša tveganje za težave, povezane s PAH, zlasti pri poslabšanje simptomov te bolezni.
English: Further information on the orphan designation can be found on the European Medicines Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Slovenian: Nadaljnje informacije glede določitve zdravila sirote lahko najdete na spletni strani Evropske agencije za zdravila: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The most common side effects with Opsumit (which may affect more than 1 in 10 people) include nasopharyngitis (inflammation of the nose and throat), anaemia (low red blood cell counts) and headache.
Slovenian: Najpogostejši neželeni učinki zdravila Opsumit (ki se lahko pojavijo pri več kot 1 bolniku od 10) so nazofaringitis (vnetje nosu in žrela), anemija (majhno število rdečih krvnih celic) in glavobol.
English: Side effects reported with Opsumit are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Opsumit, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Opsumit is a medicine used for the long-term treatment of pulmonary arterial hypertension (PAH).
Slovenian: Opsumit je zdravilo, ki se uporablja za dolgotrajno zdravljenje pljučne arterijske hipertenzije (PAH).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Opsumit have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Opsumit upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: The company that markets Opsumit will send educational material to patients and healthcare professionals with information on the precautions to be taken when using Opsumit.
Slovenian: Podjetje, ki trži zdravilo Opsumit, bo bolnikom in zdravstvenim delavcem poslalo izobraževalno gradivo z informacijami o previdnostnih ukrepih, ki jih je treba upoštevati pri uporabi tega zdravila.
English: Because more pressure is needed to force blood through the narrowed artery, this leads to high blood pressure in the lungs.
Slovenian: Ker je za pretok krvi skozi zoženo arterijo potrebna večja sila, to povzroča visok krvni tlak v pljučih.
English: Most side effects are mild to moderate in severity.
Slovenian: Neželeni učinki so večinoma blagi do zmerni.
English: Opsumit is used for adults whose PAH is classified as WHO functional class II to class III.
Slovenian: Zdravilo Opsumit se uporablja pri odraslih, pri katerih je PAH razvrščena v funkcionalni razred II do III po klasifikaciji SZO.
English: PAH is a condition in which there is abnormally high blood pressure in the arteries of the lungs, causing symptoms such as breathlessness and fatigue.
Slovenian: PAH je bolezen, za katero je značilen nenormalno visok tlak v arterijah pljuč, kar povzroča simptome, kot sta pomanjkanje sape in utrujenost.
English: Opsumit can be used alone or in combination with other PAH medicines; for further information, see the package leaflet.
Slovenian: Zdravilo Opsumit se lahko uporablja samostojno ali v kombinaciji z drugimi zdravili za zdravljenje PAH; za nadaljnje informacije glejte navodila za uporabo.
English: Around 37% of patients taking placebo had a worsening of their PAH symptoms compared with 24% of those who took Opsumit 10 mg.
Slovenian: Simptomi so se poslabšali pri približno 37 % bolnikov, ki so jemali placebo, medtem ko so se pri bolnikih, ki so jemali zdravilo Opsumit v odmerku 10 mg, poslabšali pri 24 % bolnikov.
English: PAH is ‘rare', and Opsumit was designated an ‘orphan medicine' (a medicine used in rare diseases) for PAH on 27 September 2011.
Slovenian: PAH je redka bolezen, zato je bilo zdravilo Opsumit 27. septembra 2011 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: For more information about using Opsumit, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Opsumit glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: In patients with PAH, this mechanism is overactive and, by blocking these receptors, macitentan helps widen the arteries in the lungs and thereby bring down the blood pressure.
Slovenian: Pri bolnikih s PAH je ta mehanizem čezmerno aktiven, macitentan pa te receptorje zavira in tako pripomore k razširitvi arterij v pljučih in s tem k znižanju krvnega tlaka.
English: Opsumit can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in treating PAH.
Slovenian: Predpisovanje in izdaja zdravila Opsumit je le na recept, zdravljenje pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem PAH.
English: In animal studies, Opsumit was shown to have an adverse effect on the development of embryos.
Slovenian: V študijah na živalih se je pokazalo, da zdravilo Opsumit škodljivo vpliva na razvoj zarodkov.
English: The class reflects the seriousness of the disease: patients with class II PAH have slight limitation of physical activity and those with class III disease have marked limitation of physical activity.
Slovenian: Razred opredeljuje resnost bolezni: telesna zmogljivost bolnikov s PAH razreda II je blago omejena, telesna zmogljivost bolnikov z razredom III pa je močno omejena.